Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00495872 · ClinicalTrials.gov registry record · Phase 1
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 204
- Enrollment target
NCT00495872: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00495872 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 204 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00495872, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 204 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of valproic acid in combination with either dasatinib, erlotinib hydrochloride, lapatinib, lenalidomide, sorafenib, or SU011248 (sunitinib malate) that can be given to patients with advanced cancer. The safety of each combination of the study drugs will be studied as well.
Interventions
- DRUG Lenalidomide
- DRUG Dasatinib
- DRUG Sorafenib
- DRUG Erlotinib
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2007-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00495872
The ClinicalTrials.gov registry entry for NCT00495872 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Lenalidomide is the first listed.
NCT00495872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00495872 about?
NCT00495872 is a clinical study titled "Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor". The goal of this clinical research study is to find the highest tolerable dose of valproic acid in combination with either dasatinib, erlotinib hydrochloride, lapatinib, lenalidomide, sorafenib, or SU011248 (sunitinib malate) that can be given to patients with advanced cancer. The safety of each com...
What is the current status of trial NCT00495872?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 204 participants. The study started on 2007-06.
What interventions are being tested in trial NCT00495872?
The interventions under investigation include: Lenalidomide (DRUG), Dasatinib (DRUG), Sorafenib (DRUG), Erlotinib (DRUG), Lapatinib (DRUG).
Who is sponsoring clinical trial NCT00495872?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.